Trial Profile
An Open-Label, Single-Dose, Parallel-Group Study to Compare the Pharmacokinetics of FTY720 and Metabolites in Subjects With Severe Renal Impairment With That in Matched Healthy Control Subjects.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 Dec 2020
Price :
$35
*
At a glance
- Drugs Fingolimod (Primary)
- Indications Multiple sclerosis
- Focus Pharmacokinetics
- Sponsors Novartis
- 04 Sep 2008 New trial record.